You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Novel Antagonists for Ameliorating Pulmonary Fibrosis

    SBC: AUXAGEN, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Pulmonary fibrosis, a group of incurable lung diseases with high mortality rates, is characterized by inflammatory cell infiltration, fibroblast proliferation, and excessive deposition of extracellular matrix proteins in lung parenchyma. Globally, five million people are affected by pulmonary fibrosis. In the U.S. alone, 200,000 suffer from this disease. Of the ...

    STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  2. Fast Biosequence Annotation via Reconfigurable Hardware

    SBC: BECS Technology, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Databases of biological sequences have proven valuable for understanding the organization of human and other genomes, for unraveling the etiology of genetic disorders, and for studying medically important pathogens. Unfortunately, these databases are growing at an exponential rate, posing a severe problem for bio-sequence annotation. Specialized hardware implem ...

    STTR Phase II 2007 Department of Health and Human ServicesNational Institutes of Health
  3. Rapid homogeneous antibody-based detection of proteins

    SBC: MEDIOMICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Detection of the presence and the determination of the amount of a specific protein using various techniques utilizing antibodies specific to the target protein are one of the most important tools in biomedical research, medical diagnosis and detection of biological threat agents. These techniques (such as, for example, ELISA) take advantage of the exquisite sp ...

    STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  4. High Throughput Drug Screening in Drosophila for Novel Diabetes Therapeutics

    SBC: MEDROS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Diabetes mellitus and related metabolic syndrome represent perhaps the fastest growing major disease market in the developing world. Diabetes has recently been described as "a global pandemic" that affects nearly 200 million people worldwide and costs this country more than $130 billion. Diabetes is a chronic disease characterized by a series of metabolic defec ...

    STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  5. Samaritan Compounds Suppress Viral Replication and Prevent Neuronal Damage

    SBC: SAMARITAN PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Currently up to 50% of HIV infected individuals including those taking antiretroviral therapy have mild neurocognitive disorder. Furthermore, the population living with HIV infection continues to grow and there are now over one million people living with HIV in the US and 42 million around the world. This indicates that persistent HIV associated cognitive impai ...

    STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  6. Syrian Hamster as a Permissive Model for Testing Anti-Adenovirus Drugs

    SBC: VIRRX, INC            Topic: N/A

    DESCRIPTION (provided by applicant): Human adenoviruses (Ads) are a significant problem in immunosuppressed humans, especially in children undergoing allogeneic stem cell transplants. About 20% of these pediatric patients develop disseminated Ad infections and about half of the patients die. There are no anti-viral drugs approved to treat these Ad infections. Cidofovir and ribavirin are used in so ...

    STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  7. Tiptuximab Immunotherapeutic for Cancer

    SBC: Medical Guidance Systems LLC            Topic: NCI

    ? DESCRIPTION (provided by applicant): Poor prognosis cancers such as lung cancer, glioblastoma, pancreatic cancer and others have 3 year survival rates that range from 1%-15%. Recent advancements in the development of therapeutic antibodies haveshown promise in other cancers such as breast, head and neck, and colon cancer. The limitations in antibody development are the paucity of cancer ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Galectin 1: A novel small protein therapy for Duchenne muscular dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: NIAMS

    DESCRIPTION provided by applicant Duchenne Muscular Dystrophy DMD is a fatal muscle disease affecting in every male births DMD results from mutations in the gene encoding the dystrophin a kDa scaffolding protein responsible for providing a mechanical link between the muscle fiber actin cytoskeleton and a transmembrane protein complex called the dystrophin associated glycoprotein ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Identification of Borrelia burgdorferi diagnostic biomarkers in humans and nonhum

    SBC: DxDiscovery Incorporated            Topic: NIAID

    DESCRIPTION provided by applicant The number of Lyme disease cases in the US has been recently estimated by the CDC at cases year This is major public health concern Currently available diagnostics rely on detection of the antibody response serology to Borrelia burgdorferi the causative agent of Lyme disease However serological tests are not accurate during the early stages of Ly ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Prediction and Measurement of the Carbon Build-Up in Film-Cooled Rocket Engines

    SBC: SIERRA ENGINEERING, INC.            Topic: AF15AT21

    ABSTRACT: Sierra Engineering Inc. (Sierra) believes that existing chemical kinetic models can be efficiently incorporated into commercial CFD codes to predict the mixing, pyrolysis, soot formation and carbon deposition within film cooled rocket engines. During this Phase I STTR effort we will demonstrate that this analysis capability is practical and that we can generate appropriate model validati ...

    STTR Phase I 2015 Department of DefenseAir Force
US Flag An Official Website of the United States Government